Beneficial effect of complete response and type of therapy in multiple myeloma

Autor:	Shivlal Pandey, Morie A. Gertz, Angela Dispenzieri, Stephen J. Russell, Steven R. Zeldenrust, Shaji Kumar, John A. Lust, Prashant Kapoor, Martha Q. Lacy, Robert A. Kyle, Arleigh McCurdy, S. Vincent Rajkumar, Francis K. Buadi, Suzanne R. Hayman, David Dingli
Rok vydání:	2013
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Internal medicine Medicine business medicine.disease Multiple myeloma Complete response
Zdroj:	Journal of Clinical Oncology. 31:8541-8541
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2013.31.15_suppl.8541
Popis:	8541 Background: Achievement of a complete response (CR) to treatment is an important predictor of outcome for patients (pts) with myeloma (MM). The goal of the current study was to assess whether the treatment that resulted in CR has any impact on the outcomes. Methods: We identified 462 pts with MM, who fulfilled the IMWG criteria for CR, seen at Mayo Clinic between 1991 and 2011. The treatment was classified into groups by the regimen that led to CR (Table), and also based on whether an autologous stem cell transplant (ASCT) was part of the regimen. The remaining 21 pts had a variety of regimens and are not included in the Table. Results: The median age at diagnosis was 58.5 yrs (27.1–82.3 yrs) with 56% males. The overall survival (OS) from diagnosis for the entire cohort was 10.7 yrs (95% CI; 9.3, NR). The median interval from diagnosis to the recorded CR was 10.3 mos (range 1- 170), with 272 (58.4%) and 385 (82.7%) obtaining a CR in
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2c721dd0f53b7f6fc606e6c2d52099d3 https://doi.org/10.1200/jco.2013.31.15_suppl.8541 Zobrazit plný text záznamu